Previous close | 1.2500 |
Open | 1.2500 |
Bid | 0.0000 |
Ask | 4.4000 |
Strike | 540.00 |
Expiry date | 2024-07-12 |
Day's range | 1.2500 - 1.2500 |
Contract range | N/A |
Volume | |
Open interest | 3 |
The transaction was executed at a price of $471.72 per share, as detailed in the SEC Filing. Following this sale, the insider now owns 30,099 shares of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a biotechnology firm focused on developing and commercializing therapies for the treatment of cystic fibrosis and other severe diseases.
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.